Expert digest
Credentialed experts on podcasts, in newsletters and at conferences, paraphrased with verbatim quotes, tier-coded for citation rigour.
TB-500 Q3 2026: what changed
Q3 2026 update on TB-500: four new 2026 reviews, the Topol cancer-signal status, the FDA PCAC July meeting, and WADA prohibition unchanged.
Tesamorelin Q3 2026: what changed
Q3 2026 on tesamorelin: a meta-analysis of four HIV lipodystrophy trials, a brain-connectivity pilot, a frailty trial protocol, and unchanged regulatory status.
Tirzepatide Q3 2026: what changed
EMA cardiovascular assessment, paediatric label extension, SURMOUNT-5 quality-of-life data, and the GIP mechanism question: Q3 2026 catch-up.
CJC-1295 Q3 2026: what changed
Q3 2026 update on CJC-1295: new sports-medicine reviews, Topol cancer-risk commentary, WADA detection advances, and the regulatory picture as of August 2026.
BPC-157 in Q3 2026: the FDA panel vote
The FDA's compounding panel voted 8 to 6 in July 2026 to back BPC-157 for the 503A bulks list, overruling its own reviewers. The evidence did not move.
BPC-157 in Q2 2026: what actually changed
The FDA removed BPC-157 from Category 2 in April 2026 and scheduled a PCAC review for July. The regulatory pathway shifted. The evidence picture did not.
CJC-1295 Q2 2026: what changed this quarter
CJC-1295 remains unapproved. The FDA's PCAC meets in July 2026 but CJC-1295 is not on its agenda. Two 2026 reviews confirm the clinical evidence has not moved.
Ipamorelin Q2 2026: what changed
Quarterly ipamorelin review: the HHS reclassification announcement, a still-pending FDA Category 1 move, and no new trial data.
PT-141 Q2 2026: the obesity pivot
Bremelanotide entered the obesity combination space this quarter. BMT-801 phase 2 data and next-generation MC4R compounds reshape the PT-141 picture.
What experts said about Semax this quarter
Three preclinical studies, a gerontology review and an FDA compounding meeting. What researchers published on Semax in Q2 2026.
What experts said about TB-500 in Q2 2026
On-record expert commentary on TB-500 from Q2 2026: three orthopaedic reviews, Topol's cancer-biology warning, and the upcoming FDA PCAC review.
Tesamorelin: what experts said, Q2 2026
Tesamorelin has one FDA approval and plenty of off-label hype. Here is what named experts said this quarter.